Business Description
Gyre Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US4037831033
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 81.93 | |||||
Equity-to-Asset | -0.14 | |||||
Debt-to-Equity | -0.03 | |||||
Debt-to-EBITDA | 0.02 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 6.02 | |||||
Beneish M-Score | -3.16 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 58.9 | |||||
9-Day RSI | 52.3 | |||||
14-Day RSI | 49.61 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.85 | |||||
Quick Ratio | 2.64 | |||||
Cash Ratio | 1.67 | |||||
Days Inventory | 409.52 | |||||
Days Sales Outstanding | 49.77 | |||||
Days Payable | 18.78 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | 0.02 |
Profitability Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 95.91 | |||||
Operating Margin % | 16.94 | |||||
Net Margin % | -81.92 | |||||
FCF Margin % | 15.25 | |||||
ROE % | -696.28 | |||||
ROA % | -92.34 | |||||
ROIC % | 37.91 | |||||
ROC (Joel Greenblatt) % | 68.96 | |||||
ROCE % | 22.74 | |||||
Years of Profitability over Past 10-Year | 2 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 9.14 | |||||
Price-to-Free-Cash-Flow | 59.89 | |||||
Price-to-Operating-Cash-Flow | 40.08 | |||||
EV-to-EBIT | 68.13 | |||||
EV-to-EBITDA | 64.4 | |||||
EV-to-Revenue | 11.54 | |||||
EV-to-FCF | 75.64 | |||||
Earnings Yield (Greenblatt) % | 1.47 | |||||
FCF Yield % | 1.29 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Gyre Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 104.034 | ||
EPS (TTM) (€) | -1.293 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 49.61 | ||
14-Day ATR (€) | 0.645199 | ||
20-Day SMA (€) | 14.48 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (€) | 9.85 - 24.2 | ||
Shares Outstanding (Mil) | 85.47 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Gyre Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Gyre Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Gyre Therapeutics Inc Frequently Asked Questions
What is Gyre Therapeutics Inc(FRA:L9S)'s stock price today?
When is next earnings date of Gyre Therapeutics Inc(FRA:L9S)?
Does Gyre Therapeutics Inc(FRA:L9S) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |